Using cardiac MRI and AI to predict outcomes after STEMI
Prognostic Value of Cardiac Magnetic Resonance Parameters in Patients With ST-Segment Elevation Myocardial Infarction
This project will try to use routine cardiac MRI scans plus AI to see if imaging features can predict long-term outcomes in people who had a STEMI treated with primary PCI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT07072858 on ClinicalTrials.gov |
What this trial studies
This is a prospective, multicenter observational study enrolling adults with ST-elevation myocardial infarction who undergo primary percutaneous coronary intervention. Participants receive comprehensive cardiac magnetic resonance (CMR) scanning—including cine and strain sequences—typically within seven days after PCI, and images are analyzed centrally. Advanced AI and radiomics/machine-learning methods extract high-dimensional features from multiple CMR sequences to identify imaging biomarkers reflecting myocardial structure, function, and deformation. Identified features will be tested for independent and incremental association with long-term clinical cardiovascular outcomes.
Who should consider this trial
Good fit: Adults aged 18–80 who had a confirmed ST-elevation myocardial infarction, were treated with primary PCI, can undergo CMR within seven days post-PCI, and can give informed consent are ideal candidates.
Not a fit: Patients with contraindications to MRI (incompatible implants or severe claustrophobia), recent revascularization within six months, severe valvular disease or known cardiomyopathy, marked conduction blocks that interfere with imaging, very low kidney function when contrast is anticipated, or who are pregnant or breastfeeding are unlikely to be eligible or to benefit from participation.
Why it matters
Potential benefit: If successful, the approach could help clinicians better identify patients at higher risk after STEMI so follow-up and treatments can be more precisely targeted.
How similar studies have performed: Conventional CMR markers such as infarct size, LVEF, and microvascular obstruction are established prognosticators, and emerging small-to-moderate studies using strain imaging and AI/radiomics have shown promising but not yet widely validated predictive performance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 80 years Diagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels Underwent primary percutaneous coronary intervention (PCI) Able to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI Provided written informed consent Exclusion Criteria: * Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers) History of revascularization therapy (PCI or CABG) within the previous 6 months Severe valvular heart disease or known cardiomyopathy Presence of bundle branch block or fascicular block that interferes with image interpretation Known allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences) Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² (if contrast use is anticipated) Pregnant or breastfeeding women
Where this trial is running
Beijing
- Beijing, China (Recruiting)
Study contacts
- Study coordinator: XIN A, PhD
- Email: a2013346@hotmail.com
- Phone: +8613126526196
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.